Идёт набор NCT06183762

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

— Наблюдательное Advanced Lung Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: No treatment is included in this protocol..
Кому может быть актуально: Состояния в реестре: Advanced Lung Cancer. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Китай
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive

Обзор

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Вмешательства

Другое No treatment is included in this protocol.
No drug intervention or tissue sampling will be included in this study.

Первичные конечные точки

Progression-Free-Survival [Срок оценки: Assessed up to around 4.5 years]
Overall Survival [Срок оценки: Assessed up to around 4.5 years]

Вторичные конечные точки (3)

Clinical relevance between genomic profiling and progression-free-survival [Срок оценки: Assessed up to around 4.5 years]
Clinical relevance between genomic profiling and overall survival [Срок оценки: Assessed up to around 4.5 years]
ORR [Срок оценки: Assessed up to around 4.5 years]

Критерии участия

Критерии включения

Patients must be ≥18 years of age.
Provision of fully informed consent prior to any study specific procedures.
Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
Genetic variants of tumor tissue detected by NGS.